De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification
Modern Pathology2010Vol. 24(3), pp. 384–389
Citations Over Time
Related Papers
- → Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions(2022)44 cited
- → Immunophenotype distinctions of CEBPA mutation subtypes in acute myeloid leukemia(2023)5 cited
- → Mutational Landscape of CEBPA in Mexican Pediatric Acute Myeloid Leukemia Patients: Prognostic Implications(2022)2 cited
- → Suppressed CEBPA Function Is Associated with Favorable Prognosis in Normal Karyotype AML Patients(2008)1 cited
- Studies on CEBPA mutations in acute myeloid leukaemia(2012)